Lifestyle
- Manage stress levels
- Regular physical activity
- Adequate sleep
Follikelstimulierendes Hormon · Follicle-Stimulating Hormone · FSH
FSH quantifies the concentration of follicle-stimulating hormone in the blood, reflecting pituitary function and gonadal activity.
Age Group
Reference ranges vary by sex and age; levels fluctuate during menstrual cycle in women.
Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in the regulation of the reproductive processes, including the development of ovarian follicles in women and spermatogenesis in men. FSH acts by binding to specific receptors on the surface of target cells in the ovaries and testes, stimulating the production of sex steroids and gametes. Clinically, FSH is an important marker in the evaluation of reproductive health. Elevated FSH levels can indicate primary gonadal failure, such as in conditions like menopause or testicular failure, whereas low levels may suggest secondary hypogonadism due to pituitary or hypothalamic dysfunction. In athletes and biohackers, FSH levels can be indicative of overall reproductive health and hormonal balance. However, FSH is not typically a direct target for enhancing athletic performance or longevity. Researchers have explored FSH-blocking therapies for conditions like osteoporosis, suggesting a broader role beyond reproduction. Testing for FSH levels can be influenced by several factors, including time of day, as levels may vary throughout the day. It is important to consider these variables when interpreting FSH results. Additionally, factors such as recent hormonal treatments or underlying endocrine disorders can confound FSH measurements. Therefore, careful consideration of clinical context and potential interfering factors is essential for accurate interpretation.
Klinische Bedeutung
Elevated FSH levels often indicate primary gonadal failure, such as menopause or testicular failure, while low levels may suggest secondary hypogonadism due to pituitary or hypothalamic dysfunction.
Progressively rising FSH levels may indicate worsening gonadal function; re-test in 4-6 weeks if levels are outside the normal range.
Progressively falling FSH levels may suggest recovery of gonadal function or effective treatment of underlying conditions.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider for personalized advice, especially if considering hormonal treatments.
FSH levels may vary throughout the day; consistency in timing is recommended.
Testing Frequency
Annually for reproductive health evaluation, more frequently if symptomatic.
Correlated with
Current research suggests that robust reference intervals for follicle-stimulating hormone (FSH) in various populations, particularly in women experiencing menopausal symptoms or undergoing hormone therapy, remain incomplete. Researchers have not yet established optimal FSH targets for conditions like osteoporosis and male infertility, where its role is critical. Additionally, unanswered clinical questions include the implications of elevated FSH levels in different contexts and the effects of FSH-blocking therapies on long-term health outcomes.
988
Total Citations
16
Human/RCT
4.5
Avg. Influence
2020
Latest
Researchers established detailed reference values for luteinizing hormone, follicle-stimulating hormone (FSH), estradiol, and progesterone throughout the menstrual cycle. The study involved daily hormone measurements from volunteers and aimed to aid in the interpretation of reproductive hormone results. This work contributes to better understanding of hormonal fluctuations in women.
This review examines the neuroendocrinology of menopause, comparing rodent models to human experiences. It highlights the hormonal changes and their implications, noting that while rodents show hypothalamic impairments affecting LH and FSH surges, similar irreversible changes are not evident in peri-menopausal women.
Researchers reviewed the pharmacokinetics of follicle-stimulating hormone (FSH) and found that different FSH preparations have varying effects based on their sialic acid content. They emphasized the importance of monitoring FSH levels to optimize treatment outcomes during ovulation induction.
Researchers emphasized the need for genetic testing in men with severe oligospermia or azoospermia to clarify infertility causes. They noted differences in FSH levels between obstructive and non-obstructive azoospermia, which guide appropriate genetic testing. The study highlights the evolving landscape of genetic analysis in male infertility.
Researchers developed a first-in-class FSH-blocking antibody, MS-Hu6, which showed efficacy in preventing and treating osteoporosis in mice. The study reported that MS-Hu6 localized to bone and bone marrow and demonstrated a long half-life in humanized mice. The findings suggest potential for future human testing.
Researchers discussed the expression of the follicle-stimulating hormone receptor (FSHR) in tumor blood vessels of various genitourinary malignancies. The study suggests that targeting FSHR may have therapeutic potential in treating prostate cancer and other solid tumors.
Researchers reviewed the roles of estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone (FSH) in women's health. They noted a lack of robust reference intervals for these hormones, which complicates clinical care. The study calls for collaborative efforts to better define these intervals for improved health outcomes.
Researchers examined the relationship between follicle-stimulating hormone (FSH) levels and metabolic syndrome in postmenopausal women. They found that higher FSH levels were associated with better insulin sensitivity and lower incidence of metabolic syndrome.
Researchers summarized evidence regarding the effects of FSH on bone metabolism, noting that while observational studies link FSH levels to bone loss, interventional studies have not demonstrated a direct effect. They concluded that current evidence does not support FSH as a regulator of bone or fat metabolism in humans.
13
Total Trials
1,185
Total Enrolled
Elazıg Fethi Sekin Sehir Hastanesi
73
2026
Micro-TESE Sperm Retrieval Outcome
University of Kansas Medical Center
80
2025
Pediatric FSHD-COM
University of Sheffield
50
2025
Measurement of FSH
Xiaomei Shao
106
2023
changes of serum follicle-stimulating hormone (FSH) level
Centre Hospitalier Universitaire de Nice
50
2023
Minimal clinical importance of the Motor Function Measure-32 (MFM-32) from Baseline (V1) to 18 months (V3)
Centre Hospitalier Universitaire de Nice
30
2023
Change of the Motor Function Measure-32 (MFM-32) from Baseline (T0) to 6 months (T6), 12 months (T12) and 24 months (M24)
Memorial Sloan Kettering Cancer Center
120
2021
Change in anti-Mullerian hormone (AMH), estradiol and FSH of oxaliplatin-induced gonadal toxicity in pre-menopausal female patients (<40y)
University of Kansas Medical Center
450
2020
10m walk/run
Murdoch Childrens Research Institute
11
2017
Motor Function Measure for Neuromuscular disease
Clinical Centre of Serbia
100
2014
Change of follicle-stimulating hormone (FSH)
Institut Curie
95
2013
sensitivity of blood FSH R detection in cancer patients
University of Washington
20
2006
Dutasteride can suppress the secretion of LH and FSH after four weeks of administration.
Case Comprehensive Cancer Center
0
2004
Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels
Research publications about FSH over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer